title: The Efficacy of Rituximab in High-risk Renal Transplant Recipients.
abstract: Although graft survival following renal transplantation (RTx) has improved, outcomes following highrisk RTx are variable. Preexisting antibodies, including donor-specific antibodies (DSA), play an important role in graft dysfunction and survival. We have designed a study to investigate the safety and efficacy of anti-CD20 monoclonal antibodies (rituximab) in high-risk RTx recipients. Major eligibility criteria include: 1) major and minor ABO blood group mismatch, 2) positive DSA. Thirty-five patients will receive 200 mg/body of rituximab. The primary endpoint is the incidence of B cell depletion. This study will clarify whether rituximab is efficacious in improving graft survival in high-risk RTx recipients.
authors.affiliation: Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.motoosh@md.okayama-u.ac.jp.
authors.forename: Motoo
authors.initials: M
authors.lastname: Araki
authors.forename: Koichiro
authors.initials: K
authors.lastname: Wada
authors.forename: Yosuke
authors.initials: Y
authors.lastname: Mitsui
authors.forename: Risa
authors.initials: R
authors.lastname: Kubota
authors.forename: Takashi
authors.initials: T
authors.lastname: Yoshioka
authors.forename: Yuichi
authors.initials: Y
authors.lastname: Ariyoshi
authors.forename: Yasuyuki
authors.initials: Y
authors.lastname: Kobayashi
authors.forename: Masashi
authors.initials: M
authors.lastname: Kitagawa
authors.forename: Katsuyuki
authors.initials: K
authors.lastname: Tanabe
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Sugiyama
authors.forename: Jun
authors.initials: J
authors.lastname: Wada
authors.forename: Masami
authors.initials: M
authors.lastname: Watanabe
authors.forename: Toyohiko
authors.initials: T
authors.lastname: Watanabe
authors.forename: Katsuyuki
authors.initials: K
authors.lastname: Hotta
authors.forename: Yasutomo
authors.initials: Y
authors.lastname: Nasu
mesh_terms: D000017:ABO Blood-Group System; D044466:Asian People; D001787:Blood Group Incompatibility; D002985:Clinical Protocols; D006084:Graft Rejection / Q000517:prevention & control*; D006801:Humans; D016030:Kidney Transplantation; D012107:Research Design; D000069283:Rituximab / Q000627:therapeutic use*
chemical_list: D000017:ABO Blood-Group System; D000069283:Rituximab